BackCancer Genetics Overview

Cancer Genetics Current Cash

Cancer Genetics's current cash is $2.4M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$2.44M

Peer average

Loading

Cancer Genetics Current Cash History

Loading

Cancer Genetics vs. peers: Current Cash Comparison

Loading

Cancer Genetics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Cancer Genetics (CGIX) FAQ

The latest current cash for CGIX is $2.4M as of December 2020. Investors often review this figure alongside Cancer Genetics's historical trend and sector peers before judging valuation or financial health.

A current cash figure of $2.4M for CGIX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CGIX's current cash ($2.4M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Cancer Genetics's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.